Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell
Bio-Techne Corporation is a market leader in life science reagents, well positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring revenue, near-term risks from NIH funding cuts and U.S.-China tariffs are not fully priced in. My DCF analysis suggests TECH stock is overvalued, with a fair value of $48 per share versus current high multiples; I initiate with a Sell rating.
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President & Chief Executive Officer Jim Hippel - Executive Vice President & Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Daniel Markowitz - Evercore Dan Arias - Stifel Thomas DeBourcy - Nephron Research Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode, and the call will be open for questions following the management's prepared remarks.
Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Is the Options Market Predicting a Spike in BioTechne Stock?
Investors need to pay close attention to TECH stock based on the movements in the options market lately.
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Techne (TECH) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago.
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?
Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
